Literature DB >> 6135908

Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.

K J Walker, R I Nicholson, A O Turkes, A Turkes, K Griffiths, M Robinson, Z Crispin, S Dris.   

Abstract

8 patients with advanced prostatic carcinoma were treated with the luteinising-hormone releasing-hormone agonist, ICI 118630, for up to 3 months. Patients received subcutaneous injections of ICI 118630 (either 100 micrograms or 250 micrograms daily). At the higher dose level, plasma testosterone concentrations were significantly reduced by day 14 and approximated to those previously recorded in castrated or diethylstilboestrol-treated patients. Plasma concentrations of luteinising hormone and follicle-stimulating hormone were similarly reduced. Reduction in the dose, to 100 micrograms/day, similarly reduced plasma testosterone. ICI 118630 shows considerable potential for the management of patients with advanced carcinoma of the prostate.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6135908     DOI： 10.1016/s0140-6736(83)90386-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  14 in total

Review 1.  Hormonal aspects of prostatic cancer: a review.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1985-02       Impact factor: 5.344

2.  Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.

Authors:  M Mason-Garcia; S Vigh; A M Comaru-Schally; T W Redding; A Somogyvari-Vigh; J Horvath; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

3.  The diagnosis and management of food allergy.

Authors:  A Cant
Journal:  Arch Dis Child       Date:  1986-08       Impact factor: 3.791

4.  Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.

Authors:  F Labrie; A Dupont; A Belanger; R Lachance; M Giguere
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-10

5.  Treatment of advanced carcinoma of the prostate.

Authors:  G Williams; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-08

6.  Analogues of gonadotrophin releasing hormone.

Authors:  J Waxman
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-11

7.  Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.

Authors:  T W Redding; A V Schally; T R Tice; W E Meyers
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

8.  Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.

Authors:  A V Schally; T W Redding
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

9.  Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.

Authors:  S R Ahmed; J Grant; S M Shalet; A Howell; S D Chowdhury; T Weatherson; N J Blacklock
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19

10.  Use of polymerase chain reaction for detection of toxigenic Vibrio cholerae O1 strains from the Latin American cholera epidemic.

Authors:  P I Fields; T Popovic; K Wachsmuth; O Olsvik
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.